Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2023-01-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于取得专利证书及软件著作权证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of patent certificates and software copyright certificates by the company and its subsidiaries. It lists specific patents and software copyrights obtained, and discusses the impact on the company's operations and intellectual property protection. There is no financial data, no mention of financial results, no regulatory filings or certifications, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is an official announcement of intellectual property achievements, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or others related to financial or governance disclosures. It is a regulatory announcement informing the market about new patents and copyrights. Given the content and length (1908 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-01-10 Chinese
关于2022年第四季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares for the fourth quarter of 2022 by Zhejiang Tailin Biotechnology Co., Ltd. It details the number of bonds converted, the adjusted conversion price, remaining bonds, and changes in total share capital. The document references regulatory compliance with Shenzhen Stock Exchange rules and China Securities Regulatory Commission approvals. It is a formal disclosure of bond conversion activity and resulting share capital changes, not a full financial report or earnings release. The document length is about 2510 characters, which is relatively short and focused on a specific capital event. This fits the category of Capital/Financing Update (CAP), as it updates on the company's convertible bond conversions and capital structure changes.
2023-01-03 Chinese
关于泰林转债2022年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on a convertible bond issued by Zhejiang Tailin Biotechnology Co., Ltd. It details the bond code, interest payment date, interest rate, bondholder registration date, tax information, and payment procedures. The document is relatively short (3616 characters) and focuses on the specifics of the bond interest payment rather than presenting financial statements or comprehensive financial data. It is not a full financial report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best with a Capital/Financing Update (CAP) as it relates to bond interest payment details and financing instruments.
2022-12-21 Chinese
关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a convertible bond issuance project by Zhejiang Tailin Biotechnology Co., Ltd. It details the replacement of one sponsor representative with another and includes a brief resume of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of an annual or interim report. The content is about management of the sponsorship and supervision related to a financing project, but it is not a financing update per se, rather a regulatory announcement about personnel change in the sponsor role. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-12-05 Chinese
关于取得商标注册证书、专利证书及软件著作权证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. about obtaining trademark registration certificates, patent certificates, and software copyright certificates. It details the number and types of intellectual property rights obtained, their registration numbers, and the benefits to the company. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no voting results, no management changes, no earnings information, and no mention of any report publication. The document is a regulatory announcement about intellectual property achievements, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a general regulatory announcement about company developments. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is 2344 characters, which is short and consistent with an announcement rather than a full report.
2022-12-02 Chinese
关于对深圳证券交易所关注函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Zhejiang Tailin Biotechnology Co., Ltd. responding to a letter of concern from the Shenzhen Stock Exchange. It includes extensive information about the company's NC membrane product, its R&D investment, market competition, sales figures, risk warnings, stock price fluctuations, and insider trading disclosures. The document is a regulatory response to a stock exchange inquiry, providing clarifications and risk disclosures rather than presenting financial statements or earnings results. It does not contain quarterly or annual financial reports, earnings highlights, or management discussion and analysis sections typical of financial reports. The document is longer than 5,000 characters and contains substantive content, but it is primarily a regulatory disclosure and response to a regulatory inquiry. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2022-12-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.